Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Other

Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026

 March 31, 2026

BioPharma Dive

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what s been observed over a similar timeframe in prior years, according to

OtherRead full story

Post navigation

AZ considers filings for long-acting Strensiq follow-up →
← Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com